Nektar Therapeutics is a stage-clinical biopharmaceutical company. The Сompany develops new drug candidates by applying its proprietary PEGylation and advanced polymer conjugate technologies to modify the chemical structure of substances. It is a technology supplier to a number of pharmaceutical companies including Affymax, Amgen, Merck, Pfizer and UCB Pharma, etc. Nektar Therapeuticsэ R&D pipeline of new investigational drugs includes treatments for cancer, auto-immune disease, and chronic pain.

Type
Public
HQ
San Francisco, US
Founded
1990
Size (employees)
468 (est)
Website
nektar.com
Nektar Therapeutics was founded in 1990 and is headquartered in San Francisco, US
Report incorrect company information

Key People/Management at Nektar Therapeutics

Robert Chess

Robert Chess

Chairman of the Board
Jillian Thomsen

Jillian Thomsen

Senior Vice President, Finance and Chief Accounting Officer
Dorian Hirth

Dorian Hirth

Senior Vice President, Human Resources and Facilities Operations
Timothy Riley

Timothy Riley

Senior Vice President, Technology Assessment and Quality Assurance

Nektar Therapeutics Office Locations

Nektar Therapeutics has offices in San Francisco, Huntsville and Hyderabad
San Francisco, US (HQ)
455 Mission Bay Boulevard South
Huntsville, US
1112 Church Street
Hyderabad, IN
Sy.Nos.101/2 Genome Valley Lalgadi Malakpet Shameerpet Mandal Rangareddy District Hyderabad
Show all (3)
Report incorrect company information

Nektar Therapeutics Financials and Metrics

Nektar Therapeutics Financials

Nektar Therapeutics's revenue was reported to be $307.71 m in FY, 2017
USD

Revenue (FY, 2017)

307.7 m

Gross profit (FY, 2017)

277.2 m

Gross profit margin (FY, 2017), %

90.1%

Net income (FY, 2017)

(96.7 m)

EBIT (FY, 2017)

(59.6 m)

Market capitalization (25-Apr-2018)

12.9 b

Cash (31-Dec-2017)

4.8 m
Nektar Therapeutics's current market capitalization is $12.9 b.
Annual
USDFY, 2013FY, 2014Y, 2015FY, 2016FY, 2017

Revenue

148.9 m200.7 m230.8 m165.4 m307.7 m

Revenue growth, %

35%15%(28%)

Cost of goods sold

38.5 m28.5 m34.1 m30.2 m30.5 m

Gross profit

110.4 m172.2 m196.7 m135.2 m277.2 m
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017

Revenue

60.9 m19.8 m28.5 m132.9 m108.8 m22.7 m60 m58.9 m32.8 m36.3 m24.7 m34.6 m

Cost of goods sold

12.9 m7.9 m5.1 m9.2 m8.4 m10.5 m6.8 m8.9 m7.7 m7 m6.1 m9 m

Gross profit

48 m11.9 m23.4 m123.7 m100.4 m12.1 m53.2 m50 m25.1 m29.3 m18.6 m25.6 m

Gross profit Margin, %

79%60%82%93%92%54%89%85%76%81%75%74%
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Cash

39.1 m12.4 m55.6 m59.6 m4.8 m

Accounts Receivable

Inventories

13.5 m13 m11.3 m11.1 m10.7 m

Current Assets

257.9 m288.2 m350.1 m426.3 m326.8 m
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017

Cash

65.4 m32.4 m30.7 m32 m129.5 m20.9 m18.8 m72.5 m55.7 m63.3 m23.5 m16.1 m

Accounts Receivable

4.6 m1.9 m3 m46.1 m2.9 m3.7 m3 m39.7 m27.8 m14.2 m1.6 m4.1 m

Inventories

15.1 m12.9 m14.1 m11.7 m12.5 m10.1 m10.4 m11.3 m10.3 m10.8 m13 m11 m

Current Assets

207.9 m304.8 m298.2 m324.1 m347.3 m302.2 m286.4 m344.8 m318.3 m282.5 m381 m288.2 m
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Net Income

(162 m)(53.9 m)(81.2 m)(153.5 m)(96.7 m)

Depreciation and Amortization

14.3 m12.9 m12.9 m15.4 m14.7 m

Inventories

4.8 m500 k1.6 m237 k383 k

Accounts Payable

6.2 m(6.4 m)(412 k)518 k2.1 m
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Net Income

(16.5 m)(46.2 m)(32.6 m)70.6 m33.8 m(52.7 m)(8.2 m)(19.5 m)(48.6 m)(43.2 m)(63.9 m)

Depreciation and Amortization

3 m

Inventories

14.1 m11.7 m441 k10.1 m10.4 m11.3 m10.3 m10.8 m13 m

Accounts Payable

7.4 m5.4 m2.2 m2.8 m2.3 m2.3 m2.3 m7.1 m7 m
USDY, 2017

Revenue/Employee

657.5 k

Financial Leverage

5.8 x
Show all financial metrics
Report incorrect company information

Nektar Therapeutics News and Updates

Report incorrect company information